Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer
- 6 Downloads
We decided to compare pathologic complete response (pCR) and disease-free survival (DFS) in rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy (CRT) with capecitabine plus oxaliplatin (XELOX) or capecitabine (Xeloda). In this study, patients with non-metastatic locally advanced rectal cancer (tumor stages of T2, T3, or T4) with or without lymph node involvement were retrospectively included. Patients received concomitant radiation (50.4–54 Gy external beam radiation in 28 to 30 fractions) and neoadjuvant therapy as either Xeloda (capecitabine, 2500 mg/m2 concomitantly with radiation therapy) (42patients) or XELOX [(oxaliplatin (50 mg/m2 intravenously once a week for five weeks) and capecitabine)] (72 patients). Surgery was done eight weeks after CRT. The endpoints were pCR (defined as no evidence of viable tumoral cells) and DFS (the interval from the initial treatment to the first tumor recurrence). Rectal sphincter preservation via low-anterior resection (LAR) was achieved in 73.8% of Xeloda group which was similar to XELOX group (70.8%), P = 0.61. pCR was documented in 11 (26.9%) of Xeloda group and 26 patients (36.1%) of XELOX group (P = 0.27). Tumor recurrence was recorded in 97 patients (85.1%). Mean (±SD) DFS was 52.13 (±31.92) months (median = 48 months). Mean (95% CI) DFS was 129.42 (110.19 to 148.64) in Xeloda group vs. 122.77 (110.72 to 134.83) in XELOX group (P = 0.74). Addition of oxaliplatin to capecitabine as neoadjuvant CRT for locally advanced rectal cancer did not result in improved pCR or better DFS.
KeywordsChemotherapy Capecitabine Oxaliplatin Rectal cancer
pathologic complete response
Compliance with Ethical Standards
Ethics approval and consent to participate: Ethical approval was obtained from our medical university research deputy. Informed written consent was obtained from patients.
Consent for Publication
The authors consent to publish the article.
There is no competing interest with contents of this article.
- 3.Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114–1123Google Scholar
- 9.Hirsch BR, Zafar SY (2011) Capecitabine in the management of colorectal cancer. Cancer Manag Res 3:79–89Google Scholar
- 11.Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E et al (2015) Capecitabine plus Oxaliplatin compared with fluorouracil/Folinic acid as adjuvant therapy for stage III Colon Cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 33(32):3733–3740CrossRefGoogle Scholar
- 13.Gao YH, An X, Sun WJ et al (2014) Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer. J Surg Oncol 109(5):478–482Google Scholar
- 14.Ricardi U, Racca P, Franco P, Munoz F, Fanchini L, Rondi N et al (2013) Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Med Oncol 30(2):581Google Scholar
- 15.Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M (2008) Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 98(7):1204–1209CrossRefGoogle Scholar
- 18.Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S et al (2009) Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 20(5):906–912Google Scholar
- 20.O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S et al (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and bowel project trial R-04. J Clin Oncol 32(18):1927–1934Google Scholar
- 21.Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28(10):1638–1644Google Scholar
- 23.Sha A, Abadi S, Gill S (2017) Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: a multi-Centre, retrospective, chart review study. J Oncol Pharm Pract 1078155217718381Google Scholar
- 24.Ostwal V, Engineer R, Ramaswamy A, Sahu A, Zanwar S, Arya S, Chopra S, Bal M, Patil P, Desouza A, Saklani A (2016) Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX? J Gastrointest Oncol 7(6):958–967CrossRefGoogle Scholar
- 25.Liu F, Yang L, Wu Y et al (2016) CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. Chin J Cancer Res 28(6):589–597Google Scholar
- 26.Yaghoubi A, Azadeh P, Sheibani K et al (2011) Comparison of 5FU-base Chemoradiation with and without Eloxatin on pathologic complete response in neoadjuvant Chemoradiation of rectal cancer. Iran J Pathol 6(3):110–116Google Scholar
- 29.Zeng WG, Liang JW, Wang Z, Zhang XM, Hu JJ, Hou HR, Zhou HT, Zhou ZX (2015) Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Chin J Cancer 34(10):468–474Google Scholar